

CITATION REPORT

List of articles citing

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

DOI: 10.1002/eji.1830230929

European Journal of Immunology, 1993, 23, 2242-9.

Source: <https://exaly.com/paper-pdf/23749530/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
698	The Optimization of Bioorthogonal Epitope Ligation within MHCI Complexes.		
697	Tumor-rejection antigens recognized by T lymphocytes. 1993 , 5, 701-8		38
696	Potential immunogenicity of oncogene and tumor suppressor gene products. 1993 , 5, 709-13		46
695	Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. 1994 , 179, 921-30		639
694	Use of helper T cell-inducing peptides from conserved regions in HIV-1 env in a noncovalent mixture with a CTL-inducing V3-loop peptide for in vivo induction of long-lasting systemic CTL response. 1994 , 7, 189-97		6
693	p53, a potential target for tumor-directed T cells. 1994 , 40, 171-8		75
692	Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. 1994 , 39, 105-16		47
691	Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL. <i>European Journal of Immunology</i> , 1994 , 24, 1172-80	6.1	20
690	Identification of a naturally processed HLA A0201-restricted viral peptide from cells expressing human papillomavirus type 16 E6 oncoprotein. <i>European Journal of Immunology</i> , 1994 , 24, 3175-9	6.1	30
689	Structure of peptides associated with MHC class I molecules. 1994 , 6, 13-23		166
688	Methods to study peptides associated with MHC class I molecules. 1994 , 6, 24-31		38
687	Direct analysis of tumor-associated peptide antigens. 1994 , 6, 733-40		49
686	Immunology of the human papilloma virus in relation to cancer. 1994 , 6, 746-54		61
685	Source of unique tumour antigens. 1994 , 371, 662		42
684	Enzyme immunoassay detection of induction of MHC class I expression by synthetic peptides from the E6 and E7 regions of human papillomavirus type 16. 1994 , 167, 195-205		7
683	Tumor antigens recognized by T lymphocytes. 1994 , 12, 337-65		1004
682	Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. 1994 , 31, 1391-401		65

681	Immune response against tumors. 1994 , 57, 281-351		55
680	Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. 1994 , 91, 2105-9		249
679	A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. 1995 , 101, 265-71		51
678	T cell priming versus T cell tolerance induced by synthetic peptides. 1995 , 182, 261-6		200
677	Gene transfer as cancer therapy. 1995 , 58, 417-54		109
676	Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. <i>European Journal of Immunology</i> , 1995 , 25, 2638-42	6.1	137
675	Biologic treatment of human cancer. 1995 , 19, 190-261		3
674	MHC ligands and peptide motifs: first listing. 1995 , 41, 178-228		1444
673	Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7. 1995 , 42, 317-23		32
672	Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice. 1995 , 42, 557-63		34
671	Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. 1995 , 1, 1179-83		127
670	Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. 1995 , 1, 1297-302		936
669	Can co-stimulated tumor immunity be therapeutically efficacious?. 1995 , 145, 123-45		71
668	T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. 1995 , 145, 167-77		96
667	Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization. 1995 , 47, 1-8		16
666	Prediction of binding to MHC class I molecules. 1995 , 185, 181-90		67
665	Animal models of human-derived cancer vaccines. 1995 , 27, 15-30		5
664	Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation. 1995 , 14, 77-97		15

663	Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape. 1995 , 23, 692-6	6
662	Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. 1995 , 2, 289-99	206
661	An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. 1995 , 44, 189-98	72
660	In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. 1995 , 13, 313-20	44
659	Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16. 1995 , 8, 165-74	28
658	A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. 1995 , 269, 1281-4	971
657	A helper T-cell epitope of the E7 protein of human papillomavirus type 16 in BALB/c mice. 1995 , 37, 13-22	3
656	Induction of rat CD4+ proliferative and mouse CD8+ cytotoxic T-cell lines specific for human papillomavirus type 16 antigens. 1996 , 147, 301-11	1
655	Papillomavirus: Agents infectieux et oncogènes. 1996 , 11, 104-114	
654	Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen. 1996 , 14, 545-52	54
653	Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. 1996 , 62, 33-41	36
652	A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. 1996 , 347, 1523-7	434
651	Minimal phenotype panels. A method for achieving maximum population coverage with a minimum of HLA antigens. 1996 , 51, 95-8	30
650	Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. 1996 , 14, 1523-30	106
649	Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. 1996 , 14, 1485-94	83
648	Identification of potential CTL epitopes of bovine RSV using allele-specific peptide motifs from bovine MHC class I molecules. 1996 , 54, 211-9	10
647	MHC class I-restricted CTL responses to exogenous antigens. 1996 , 5, 295-302	229
646	A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. 1996 , 5, 115-24	170

645	The rat cim effect: TAP allele-dependent changes in a class I MHC anchor motif and evidence against C-terminal trimming of peptides in the ER. 1996 , 4, 159-65	105
644	Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. 1996 , 2, 241-51	13
643	The current status of therapeutic HPV vaccine. 1996 , 28, 471-7	19
642	Influence of host and parasite genotypes on immunological control of Theileria parasites. 1996 , 112, S53-S66	22
641	Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. 1996 , 93, 7855-60	245
640	p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. 1996 , 93, 4781-6	101
639	Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. 1996 , 49, 1-56	61
638	Immunity to Human Papillomavirus-Associated Cervical Neoplasia. 1996 , 69, 175-211	33
637	In vivo CTL immunity can be elicited by in vitro reconstituted MHC/peptide complex. 1996 , 192, 105-15	9
636	HLA control in the progression of human papillomavirus infections. 1996 , 7, 359-71	62
635	HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. 1996 , 42, 151-60	44
634	Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. 1996 , 43, 44-8	32
633	Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. 1996 , 175, 1586-93	73
632	Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. <i>European Journal of Immunology</i> , 1996 , 26, 435-43	6.1 52
631	Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts. 1996 , 66, 686-91	11
630	Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. 1996 , 67, 303-10	47
629	Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. 1996 , 67, 595-602	56
628	Peptide-based cancer vaccines. 1996 , 8, 651-7	68

627	Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides. 1996 , 105, 369-75	10
626	New peptide and protein drugs. 1996 , 18, 87-93	11
625	Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes. 1996 , 184, 121-30	60
624	Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. 1996 , 77 (Pt 7), 1585-93	50
623	T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. 1996 , 77 (Pt 9), 2183-91	56
622	Protection against papillomavirus with a polynucleotide vaccine. 1996 , 173, 314-20	145
621	IL-2 as adjuvant for vaccination with cells malignantly converted by HPV 16 or 3-MC. 1996 , 8, 477-81	
620	Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. 1997 , 89, 1285-93	130
619	Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. 1997 , 186, 695-704	183
618	Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. 1997 , 20, 276-86	77
617	Melanoma vaccines: prospects for the treatment of melanoma. 1997 , 6, 267-27	6
616	Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. 1997 , 22, 219-25	34
615	Activation or frustration of anti-tumor responses by T-cell-based immune modulation. 1997 , 9, 323-7	10
614	Cellular immunity in cutaneous and genital HPV infections. 1997 , 15, 261-74	20
613	Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). 1997 , 53, 81-9	39
612	Modulation of antigen processing and presentation by persistent virus infections and in tumors. 1997 , 54, 104-16	15
611	Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. 1997 , 94, 14660-5	76
610	The evolution of anti-tumor immunotherapy. 1997 , 108, 695-7	1

609	The roles of the human major histocompatibility complex and human papillomavirus infection in cervical intraepithelial neoplasia and cervical cancer. 1997 , 9, 4-13		13
608	E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein. 1997 , 231, 155-65		23
607	Chimeric papillomavirus-like particles. 1997 , 234, 93-111		163
606	A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. 1997 , 234, 261-6		51
605	Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. 1997 , 235, 94-103		55
604	Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. 1997 , 15, 94-103		113
603	Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. <i>European Journal of Immunology</i> , 1997 , 27, 2391-9	6.1	65
602	Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. <i>European Journal of Immunology</i> , 1997 , 27, 2702-7	6.1	109
601	Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. 1997 , 73, 125-30		41
600	Tumor-Associated Antigen Peptides as Anti-Metastatic Vaccines. 1998 , 5, 323-328		
599	Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. 1998 , 240, 147-57		98
598	Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. 1998 , 244, 352-64		39
597	L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. 1998 , 250, 371-6		65
596	Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. 1998 , 252, 39-45		74
595	Cancer vaccines. 1998 , 4, 525-31		441
594	Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. 1998 , 78, 196-201		85
593	Split tolerance to a viral antigen expressed in thymic epithelium and keratinocytes. <i>European Journal of Immunology</i> , 1998 , 28, 2791-800	6.1	33
592	The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. <i>European Journal of Immunology</i> , 1998 , 28, 4010-9	6.1	60

591	Epidemiologie, Biologie und Prävention des Zervixkarzinoms. 1998 , 4, 110-123	1
590	Tumor-associated antigen peptides as anti-metastatic vaccines. 1998 , 5, 323-328	
589	Experimental vaccine strategies for cancer immunotherapy. 1998 , 5, 231-52	78
588	The role of CD4+ T cell responses in antitumor immunity. 1998 , 10, 588-94	531
587	Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term. 1998 , 47, 459-65	35
586	Overlapping epitopes of friend murine leukemia virus gag-encoded leader sequence recognized by single cytotoxic T-lymphocyte clones. 1998 , 62, 33-8	4
585	Is vaccination against human papillomavirus a possibility?. 1998 , 351 Suppl 3, 22-4	24
584	Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge. 1998 , 16, 613-23	38
583	High structural side chain specificity required at the second position of immunogenic peptides to obtain stable MHC/peptide complexes. 1998 , 421, 95-9	12
582	6 Preparation and Use of Adjuvants. 1998 , 25, 471-502	4
581	Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. 1998 , 187, 693-702	475
580	Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. 1998 , 90, 287-94	72
579	Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. 1998 , 12, 1229-35	2
578	Papillomaviruses and cervical cancer: pathogenesis and vaccine development. 1998 , 27-30	24
577	Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. 1998 , 95, 1800-5	272
576	Papillomavirus vaccines. 1998 , 3, D1192-208	14
575	References. 1999 , 319-374	
574	T(h)1 but not T(h)0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides. 1999 , 11, 2025-34	19

573	Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. 1999 , 10, 2727-40	191
572	Enhanced cleavage of diaminopimelate-containing isopeptides by leucine aminopeptidase and matrix metalloproteinases in tumors: application to bioadhesive peptides. 1999 , 53, 177-87	
571	Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. 1999 , 115, 397-403	40
570	The use of vaccines in treating cervical cancer: present status and future prospects. 1999 , 9, 265-278	10
569	CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. 1999 , 5, 774-9	406
568	Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. 1999 , 6, 73-80	65
567	Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response. 1999 , 6, 331-9	30
566	Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. 1999 , 6, 1972-81	70
565	Effects of TGF-beta on the immune system: implications for cancer immunotherapy. 1999 , 13, 1188-99	127
564	Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer. 1999 , 74, 448-55	18
563	CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. 1999 , 18, 143-50	45
562	Epidemiologie, Biologie und Prävention des Zervixkarzinoms. 1999 , 32, 247-260	1
561	Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. 1999 , 30, 269-74	55
560	Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. 1999 , 81, 881-8	101
559	Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. 1999 , 35, 946-52	186
558	Immunotherapeutic strategies for cervical squamous carcinoma. 1999 , 13, 259-73	9
557	Synthetic peptides as vaccines. 1999 , 281-317	10
556	The BCR-ABL Oncoprotein and Immunological Targeting - Vaccination for Tumor Prevention and Therapy. 2000 ,	

555	Peptide Vaccination in Clinical Oncology. 2000 , 23, 410-415	6
554	Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. 2000 , 23, 255-66	133
553	Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. 2000 , 88, 92-98	77
552	Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. 2000 , 121, 216-25	138
551	Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. 2000 , 78, 580-5	60
550	Immunology and immunotherapy of human cancer: present concepts and clinical developments. 2000 , 34, 1-25	59
549	HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented. 2000 , 71, 55-9	13
548	Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. 2000 , 7, 726-33	97
547	Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. 2000 , 7, 1859-66	46
546	Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. 2000 , 273, 374-82	48
545	Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development. 2000 , 277, 48-57	17
544	The role of CD40 in peripheral T cell tolerance and immunity. 2000 , 78, 363-71	61
543	Tumour vaccines: a new immunotherapeutic approach in oncology. 2000 , 79, 651-9	5
542	Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. 2000 , 7, 341-56	34
541	Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. 2000 , 96, 91-99	123
540	IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. 2000 , 165, 5502-8	86
539	MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. 2000 , 164, 4500-6	99
538	Identification and characterization of a novel protein from Sertoli cells, PASS1, that associates with mammalian small stress protein hsp27. 2000 , 275, 18724-31	28

537	Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. 2000 , 165, 539-47	121
536	Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site. 2000 , 164, 1898-905	85
535	4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. 2000 , 164, 2320-5	116
534	The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. 2000 , 165, 3301-8	121
533	Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. 2000 , 74, 9083-9	56
532	Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. 2000 , 74, 2888-94	129
531	Reverse immunogenetic and polyepitopic approaches for the induction of cell-mediated immunity against bovine viral pathogens. 2000 , 1, 103-18	4
530	Dendritic cells in cancer immunotherapy. 2000 , 18, 245-73	576
529	Evaluation of T-cell responses to peptides and lipopeptides with MHC class I binding motifs derived from the amino acid sequence of the 19-kDa lipoprotein of Mycobacterium tuberculosis. 2000 , 37, 413-22	11
528	The immunology of animal papillomaviruses. 2000 , 73, 101-27	50
527	Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. 2000 , 61, 764-79	69
526	Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. 2000 , 18, 1327-33	56
525	Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. 2000 , 18, 2015-22	69
524	Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. 2000 , 18, 2444-53	50
523	Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. 2000 , 182, 595-8	130
522	Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver. 2000 , 33, 91-8	19
521	Strategies for immunotherapy of cancer. 2000 , 75, 235-82	118
520	Gene expression analysis in human monocytes, monocyte-derived dendritic cells, and alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. 2001 , 289, 531-8	8

519	Individuation of monoclonal anti-HPV16 E7 antibody linear peptide epitope by computational biology. 2001 , 22, 1981-5	26
518	Therapeutic potential of protein and adjuvant vaccinations on tumour growth. 2001 , 19, 2583-9	49
517	Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. 2001 , 19, 2549-56	80
516	Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. 2001 , 19, 3652-60	105
515	Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. 2001 , 19, 3608-14	35
514	A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. 2001 , 19, 4276-86	47
513	Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. 2001 , 20, 813-25	28
512	Novel immunologic approaches to the management of malignant melanoma. 2001 , 13, 124-8	9
511	Immunity to human papillomaviruses: Implications for vaccine design. 2001 , 5, 451-478	1
510	Targets for immunotherapy in breast cancer. 2001 , 10, 23-26	2
509	Therapeutic vaccines for human papillomaviruses. 2001 , 44, 167-75	31
508	Clinical approaches to vaccination in oncology. 2001 , 80, 255-66	7
507	Prophylactic and therapeutic vaccines for genital papillomavirus infection. 2001 , 6, 238-43	4
506	HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. 2001 , 92, 285-93	57
505	Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. 2001 , 94, 825-33	121
504	Cervical cancer vaccines: emerging concepts and developments. 2001 , 186, 169-82	69
503	The identification of a common pathogen-specific HLA class I A*0201-restricted cytotoxic T cell epitope encoded within the heat shock protein 65. <i>European Journal of Immunology</i> , 2001 , 31, 3602-11	6.1 24
502	Synthetic peptides induce a cytotoxic response against human papillomavirus type-18. 2001 , 82, 77-83	7

501	Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. 2001 , 279, 354-60	43
500	Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells. 2001 , 281, 231-8	85
499	Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. 2001 , 290, 350-60	55
498	Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. 2001 , 8, 128-38	23
497	Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. 2001 , 8, 376-83	98
496	A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay. 2001 , 254, 59-66	52
495	Cervical cancer: prevention, diagnosis, and therapeutics. 2001 , 51, 92-114; quiz 115-8	101
494	Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. 2001 , 166, 5366-73	143
493	Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. 2001 , 166, 5733-40	132
492	Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. 2001 , 167, 2522-8	50
491	Cell-mediated immune response to human papillomavirus infection. 2001 , 8, 209-20	159
490	Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. 2001 , 166, 5398-406	438
489	Vaccines in oncology: background and clinical potential. 2001 , 74, 991-1002	7
488	Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. 2001 , 12, 235-52	63
487	Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. 2001 , 166, 6218-26	56
486	Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. 2001 , 75, 2368-76	71
485	Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. 2001 , 167, 6471-9	242
484	Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide. 2001 , 166, 7151-7	28

483	Vaccination for malignant melanoma: recent developments. 2001 , 60, 1-7	54
482	Nonspecific down-regulation of CD8+ T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter. 2001 , 75, 5985-97	17
481	Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. 2001 , 167, 6180-7	43
480	Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. 2001 , 75, 9654-64	81
479	The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. 2001 , 1, 665-76	34
478	The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. 2002 , 86, 113-48	27
477	Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. 2002 , 169, 350-8	347
476	Detection of CD4(+) and CD8(+) T-cell responses to human papillomavirus type 1 antigens expressed at various stages of the virus life cycle by using an enzyme-linked immunospot assay of gamma interferon release. 2002 , 76, 6027-36	21
475	Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. 2002 , 76, 2676-82	81
474	Animal models for development of therapeutic HPV16 vaccines (Review). 2002 , 20, 207	
473	HPV induced cervical carcinogenesis: molecular basis and vaccine development. 2002 , 124, 511-24	14
472	Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes. 2002 , 45, 24-32	31
471	Cervical Cancer Vaccines: Progress and Prospects. 2002 , 9, 254-264	3
470	T cell response to human papillomavirus 16 E7 in mice: comparison of Cr release assay, intracellular IFN-gamma production, ELISPOT and tetramer staining. 2002 , 45, 290-9	23
469	Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. 2002 , 45, 300-7	20
468	Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. 2002 , 13, 553-68	105
467	Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. 2002 , 94, 805-18	335
466	Therapeutic vaccination against chronic viral infections. 2002 , 2, 353-67	23

465	The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. 2002 , 89, 275-84	25
464	Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. 2002 , 20, 3456-64	123
463	. 2002 ,	5
462	Immunotherapy of human papillomavirus-associated malignancies and the challenges posed by T-cell tolerance. 2002 , 7, d853-71	4
461	Hybrid Cell Vaccination for Cancer Immune Therapy. 2002 , 230-252	
460	Oral vaccination with recombinant <i>Listeria monocytogenes</i> expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. 2002 , 102, 629-37	51
459	Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen. 2002 , 97, 58-63	8
458	Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. 2002 , 9, 675-687	23
457	Identification of two homologous antigenic peptides derived from L1 HPV-16 and 18 proteins specific for the HLA-B*3901 allele. 2002 , 147, 1933-42	7
456	Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8. 2002 , 106, 395-403	43
455	Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. 2002 , 106, 526-36	24
454	Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. 2002 , 80, 21-9	24
453	Interferon-gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. 2002 , 80, 415-24	24
452	Studies towards the potential of poliovirus as a vector for the expression of HPV 16 virus-like-particles. 2002 , 34, 201-8	7
451	Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. 2002 , 294, 47-59	66
450	Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. 2002 , 301, 43-52	80
449	Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. 2003 , 129, 511-20	33
448	New approaches for the management of cervical cancer. 2003 , 90, S22-7	28

447	Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. 2003 , 81, 1-7	20
446	CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. 2003 , 10, 1311-20	49
445	Allogeneic breast cancer cell vaccines. 2003 , 3 Suppl 4, S173-80	13
444	Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. 2003 , 21, 1082-8	52
443	Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation. 2003 , 21, 2506-15	7
442	Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. 2003 , 21, 3219-27	46
441	Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. 2003 , 21, 4036-42	145
440	Tumor-associated antigens: from discovery to immunity. 2003 , 22, 81-112	33
439	Identification and characterisation of a group of cervical carcinoma patients with profound downregulation of intratumoral Type 1 (IFNgamma) and Type 2 (IL-4) cytokine mRNA expression. 2003 , 39, 595-603	20
438	Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. 2003 , 31, 225-31	28
437	Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. 2003 , 7, 640-8	62
436	Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. 2003 , 170, 2912-22	62
435	In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. 2003 , 171, 2912-21	49
434	Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. 2003 , 77, 4635-45	85
433	Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. 2003 , 8, 559-66	38
432	A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. 2003 , 14, 1389-99	42
431	Preventative and therapeutic vaccines for cervical cancer. 2003 , 2, 495-516	32
430	IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. 2003 , 171, 4765-72	46

429 Principles of Cancer Immunotherapy. **2003**, 79-93

428 Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. **2003**, 14, 345-62 55

427 Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. **2003**, 171, 4121-30 46

426 Advances in immunotherapy for prostate cancer. **2003**, 87, 159-194 6

425 HPV DNA vaccines. **2003**, 8, d55-68 27

424 Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. **2004**, 15, 167-77 58

423 Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. **2004**, 96, 1611-9 51

422 Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. **2004**, 78, 1333-43 47

421 Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. **2004**, 101, 13239-44 104

420 Handbook of Cancer Vaccines. **2004**, 5

419 Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. **2004**, 173, 6753-9 144

418 Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. **2004**, 78, 8468-76 102

417 Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future?. **2004**, 15, 197-200 15

416 Human growth hormone presented by K14hGH-transgenic skin grafts induces a strong immune response but no graft rejection. **2004**, 82, 577-86 6

415 CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. **2004**, 112, 117-25 41

414 Tumour susceptibility to innate and adaptive immunotherapy changes during tumour maturation. **2004**, 82, 455-61 3

413 DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. **2004**, 11, 457-64 25

412 Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. **2004**, 11, 924-32 76

411	Comparison of HPV DNA vaccines employing intracellular targeting strategies. 2004 , 11, 1011-8	95
410	Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. 2004 , 23, 3972-9	31
409	A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. 2004 , 92, 957-64	42
408	Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. 2004 , 22, 520-7	85
407	Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. 2004 , 22, 3993-4001	52
406	Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. 2004 , 23, 305-11	12
405	Vaccination to prevent and treat cervical cancer. 2004 , 35, 971-82	88
404	Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model. 2004 , 27, 303-7	10
403	Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. 2005 , 11, 3485-500	39
402	Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. 2005 , 7, 1541-50	26
401	Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. 2005 , 1056, 328-43	29
400	Human papillomavirus infection: biology, epidemiology, and prevention. 2005 , 15, 727-46	165
399	Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. 2005 , 116, 255-66	41
398	HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients. 2005 , 96, 92-102	18
397	Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice. 2005 , 96, 475-83	10
396	Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. 2005 , 99, S251-61	34
395	Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. 2005 , 114, 606-12	16
394	Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy. 2005 , 7, 686-95	47

393	Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect. 2005 , 7, 696-707	6
392	A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour. 2005 , 54, 157-71	18
391	Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. 2005 , 54, 477-88	27
390	Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin. 2005 , 12, 279-87	9
389	Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. 2005 , 12, 1410-4	36
388	Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. 2005 , 65, 9089-98	44
387	Presence and influence of human papillomaviruses (HPV) in Tonsillar cancer. 2005 , 93, 59-89	44
386	Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. 2005 , 65, 9525-35	244
385	Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. 2005 , 16, 584-93	58
384	Tumor Immunology and Cancer Vaccines. 2005 ,	2
383	Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. 2005 , 11, 4601-9	53
382	A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. 2005 , 175, 7297-302	162
381	Human Papillomavirus Vaccine for Cervical Cancer: Where Are We Now?. 2005 , 44, 232-241	4
380	Emerging human papillomavirus vaccines. 2005 , 10, 5-19	28
379	Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. 2005 , 23, 1149-57	26
378	Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. 2005 , 23, 3864-74	27
377	Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. 2005 , 23, 5768-74	25
376	Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. 2005 , 13, 89-98	68

375	New Concepts of Antiviral Therapy. 2006 ,	
374	Development of a topical protein therapeutic for human papillomavirus and associated cancers. 2006 , 20, 209-18	6
373	Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. 2006 , 4, 42	26
372	Vaccination for treatment and prevention of cancer in animal models. 2006 , 90, 175-213	70
371	An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. 2006 , 24, 2880-93	44
370	Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. 2006 , 24, 5235-44	65
369	Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. 2006 , 24, 5360-70	41
368	Exploiting the Plant Secretory Pathway to Improve the Anticancer Activity of a Plant-Derived HPV16 E7 Vaccine. 2006 , 19, 205873920601900	35
367	Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. 2006 , 29, 32-40	21
366	Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. 2006 , 29, 250-60	40
365	Tumor-infiltrating T lymphocytes: friends or foes?. 2006 , 86, 231-45	218
364	Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. 2006 , 13, 873-85	25
363	Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. 2006 , 13, 67-77	39
362	A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. 2006 , 13, 257-65	41
361	Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition. 2006 , 107, 41-9	20
360	Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. 2006 , 58, 916-30	91
359	Papillomavirus and treatment. 2006 , 71, 181-91	35
358	Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. 2006 , 118, 364-72	24

357	Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. 2006 , 118, 2514-21	12
356	Human papillomaviruses and cervical cancer. 2006 , 66, 125-59	45
355	Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice. 2006 , 80, 2034-44	65
354	Antitumor therapeutic effects of e7 subunit and DNA vaccines in an animal cervical cancer model: antitumor efficacy of e7 therapeutic vaccines is dependent on tumor sizes, vaccine doses, and vaccine delivery routes. 2006 , 25, 277-86	19
353	Human papillomavirus vaccines for the treatment of cervical cancer. 2006 , 5, 783-92	11
352	In vivo bactofection: listeria can function as a DNA-cancer vaccine. 2006 , 25, 142-51	26
351	Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. 2006 , 80, 3975-84	47
350	Targeted therapy of DNA tumor virus-associated cancers using virus-activated transcription factors. 2006 , 13, 899-909	24
349	Chimeric DNA vaccine reverses morphine-induced immunosuppression and tumorigenesis. 2006 , 13, 203-10	20
348	Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. 2006 , 66, 960-9	76
347	Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcγ receptors and contributes to acquisition of T cell immunity. 2007 , 178, 7587-97	50
346	Effects of intranasal administration of a leptin-secreting <i>Lactococcus lactis</i> recombinant on food intake, body weight, and immune response of mice. 2007 , 73, 5300-7	29
345	Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein. 2007 , 14, 1013-23	19
344	HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. 2007 , 81, 1412-23	30
343	IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways. 2007 , 15, 1890-7	22
342	Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity. 2007 , 15, 1564-70	41
341	Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. 2007 , 13, 341-9	57
340	Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70. 2007 , 67, 10047-57	25

339	Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. 2007 , 67, 8847-55	84
338	Mechanisms used by human papillomaviruses to escape the host immune response. 2007 , 7, 79-89	162
337	In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. 2007 , 67, 1344-51	85
336	The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. 2007 , 25, 3437-44	15
335	Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. 2007 , 25, 3302-10	30
334	Co-immunisation with DNA encoding RANK/RANKL or 4-1BBL costimulatory molecules does not enhance effector or memory CTL responses afforded by immunisation with a tumour antigen-encoding DNA vaccine. 2007 , 25, 5209-19	4
333	The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. 2007 , 25, 5882-91	40
332	Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours. 2007 , 25, 6037-46	20
331	Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. 2007 , 25, 6581-8	66
330	Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. 2007 , 7, 1473-86	27
329	Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. 2007 , 204, 879-91	104
328	Human papillomavirus therapeutic vaccines in head and neck tumors. 2007 , 7, 753-66	15
327	Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. 2007 , 67, 2339-44	43
326	CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. 2007 , 179, 5033-40	182
325	Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. 2007 , 5, 26	29
324	Design and development of synthetic peptide vaccines: past, present and future. 2007 , 6, 591-603	105
323	Immunotherapeutic Strategies against Cancer using <i>Listeria monocytogenes</i> as a Vector for Tumor Antigens. 2007 , 113-129	
322	DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection. <i>European Journal of Immunology</i> , 2007 , 37, 376-84	6.1 25

321	A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. 2007 , 14, 1695-704		26
320	Expression of the costimulatory molecule CD86, but not CD80, in keratinocytes of normal cervical epithelium and human papillomavirus-16 positive low squamous intraepithelial lesions. 2007 , 17, 571-80		9
319	Multiple copies of a tumor epitope in a recombinant hepatitis B surface antigen (HBsAg) vaccine enhance CTL responses, but not tumor protection. 2007 , 368, 363-75		3
318	A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses. 2007 , 104, 199-206		9
317	DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. 2007 , 107, 404-12		26
316	Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. 2008 , 57, 789-97		15
315	Mutation in the immunodominant epitope of the HPV16 E7 oncoprotein as a mechanism of tumor escape. 2008 , 57, 823-31		12
314	Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region. 2008 , 46, 728-36		12
313	Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11. 2008 , 300, 235-42		7
312	Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. 2008 , 122, 247-59		49
311	Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. <i>European Journal of Immunology</i> , 2008 , 38, 1033-42	6.1	136
310	Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. 2008 , 5, 464-71		50
309	Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. 2008 , 15, 1007-16		27
308	Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. 2008 , 15, 1156-66		25
307	Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. 2008 , 8, 351-60		436
306	Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG). 1995 , 100, 186-93		51
305	Generation and characterization of a preventive and therapeutic HPV DNA vaccine. 2008 , 26, 351-60		48
304	A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. 2008 , 26, 1387-96		39

303	Viruses in head and neck cancers: prevention and therapy. 2008 , 8, 1365-71	1
302	Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. 2008 , 15, 937-45	17
301	Human papillomavirus in cervical and head-and-neck cancer. 2008 , 5, 24-31	187
300	Optimizing approaches to head-and-neck cancers. Viruses in head-and-neck cancers: prevention and therapy. 2008 , 19 Suppl 7, vii189-94	3
299	Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein. 2008 , 15, 817-24	24
298	Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice. 2008 , 7, 1329-35	25
297	Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. 2008 , 76, 1940-51	40
296	Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. 2008 , 17, 189-95	71
295	HBsAg-vectored DNA vaccines elicit concomitant protective responses to multiple CTL epitopes relevant in human disease.. 2008 ,	
294	Cervical Cancer-Associated Human Papillomavirus 16 E7 Oncoprotein Inhibits Induction of Anti-Cancer Immunity by a CD4+ T Cell Dependent Mechanism. 2009 ,	
293	Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses. 2009 , 106, 8314-9	26
292	IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. 2009 , 183, 51-8	38
291	Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. 2009 , 15, 6167-76	24
290	Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. 2009 , 15, 6560-9	97
289	Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. 2009 , 17, 906-13	24
288	Her-2/neu Transgenic Mice for Evaluation of Immune and Antitumor Responses Against Self-Tumor Antigens in the Young and the Old. 2009 , 1189-1216	
287	Combination of viral oncolysis and tumor-specific immunity to control established tumors. 2009 , 15, 4581-8	17
286	Recombinant adeno-associated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vaccine for nasopharyngeal carcinoma. 2009 , 8, 2754-61	15

285	Interaction of human papillomaviruses with the host immune system: a well evolved relationship. 2009 , 384, 410-4	130
284	The therapeutic vaccine: is it feasible?. 2009 , 40, 493-8	14
283	Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. 2009 , 125, 189-98	31
282	Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+CD25+ T cells. <i>European Journal of Immunology</i> , 2009 , 39, 481-90	6.1 32
281	Construction and humoral immune response of Epstein-Barr virus latent membrane protein 2 DNA vaccine in mice. 2009 , 3, 390-395	
280	Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. 2009 , 69, 571-84	75
279	Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression. 2009 , 128, e707-17	10
278	Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects. 2009 , 16, 776-87	15
277	Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. 2009 , 27, 431-40	59
276	Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. 2009 , 27, 701-7	18
275	Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. 2009 , 27, 1040-9	43
274	Vaccination with human papillomavirus type 16-derived peptides using a tattoo device. 2009 , 27, 3519-29	21
273	li-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers. 2009 , 27, 4641-7	4
272	HPV and Therapeutic Vaccines: Where are We in 2010?. 2010 , 6, 81-103	31
271	Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. 2010 , 36, 545-51	23
270	Human papillomavirus vaccines in plants. 2010 , 9, 913-24	40
269	Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy. 2010 , 59, 1049-1058	18
268	HBsAg-vectored vaccines simultaneously deliver CTL responses to protective epitopes from multiple viral pathogens. 2010 , 398, 68-78	3

267	Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. 2010 , 126, 2469-78	14
266	Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. 2010 , 17, 88	70
265	Hepatitis B surface antigen fusions delivered by DNA vaccination elicit CTL responses to human papillomavirus oncoproteins associated with tumor protection. 2010 , 17, 708-20	8
264	Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70. 2010 , 21, 109-19	22
263	Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice. 2010 , 9, 134-41	17
262	Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. 2010 , 17, 1576-83	21
261	Combination of adoptive cell transfer and antibody injection can eradicate established tumors in mice--an in vivo study using anti-OX40mAb, anti-CD25mAb and anti-CTLA4mAb-. 2010 , 32, 238-45	9
260	Morphine-sparing effect by COX-1 inhibitor sustains analgesic function without compromising antigen-specific immunity and antitumor effect of naked DNA vaccine. 2010 , 23, 91-104	6
259	Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. 2010 , 70, 3955-64	27
258	Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. 2010 , 28, 2810-7	64
257	Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. 2010 , 28, 4275-82	9
256	Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis. 2010 , 28, 7146-54	8
255	DNA vaccine with β -galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. 2010 , 28, 7297-305	34
254	Perspectives for the development of human papillomavirus vaccines and immunotherapy. 2010 , 9, 35-44	13
253	A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. 2010 , 285, 29608-22	57
252	Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18. 2011 , 8, 302	11
251	The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine. 2011 , 19, 2249-57	19
250	The HPV transcriptome in HPV16 positive cell lines. 2011 , 25, 108-13	22

249	A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice. 2011 , 29, 920-30	30
248	Screening and identification of T helper 1 and linear immunodominant antibody-binding epitopes in the spike 2 domain and the nucleocapsid protein of feline infectious peritonitis virus. 2011 , 29, 1791-800	16
247	MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model. 2011 , 29, 4125-31	9
246	A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. 2011 , 29, 7857-66	26
245	Bone marrow vaccination: a novel approach to enhance antigen specific antitumor immunity. 2011 , 29, 8599-605	3
244	Titanium salan complexes displays strong antitumor properties in vitro and in vivo in mice. 2011 , 6, e17869	38
243	Immunoprotectivity of HLA-A2 CTL peptides derived from respiratory syncytial virus fusion protein in HLA-A2 transgenic mouse. 2011 , 6, e25500	11
242	Enhanced anti-tumor effect of a gene gun-delivered DNA vaccine encoding the human papillomavirus type 16 oncoproteins genetically fused to the herpes simplex virus glycoprotein D. 2011 , 44, 421-7	9
241	Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. 2011 , 18, 407-18	19
240	DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. 2011 , 1, 26	5
239	The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. 2011 , 128, 473-81	30
238	Enhancement of DNA vaccine potency by antigen linkage to IFN-Inducible protein-10. 2011 , 128, 702-14	18
237	A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers. 2011 , 128, 2105-13	29
236	Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. 2011 , 19, 805-14	32
235	Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. 2011 , 22, 809-19	29
234	Antitumor therapeutic and antimetastatic activity of electroporation-delivered human papillomavirus 16 E7 DNA vaccines: a possible mechanism for enhanced tumor control. 2011 , 30, 975-85	16
233	Advances in peptide-based human papillomavirus therapeutic vaccines. 2012 , 12, 1581-92	43
232	TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. 2012 , 61, 1307-17	55

231	A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers. 2012 , 170, 44-52	14
230	Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. 2012 , 127, 412-9	61
229	Synthesis and X-ray structure analysis of a heptacoordinate titanium(IV)-bis-chelate with enhanced in vivo antitumor efficacy. 2012 , 48, 5790-2	44
228	A novel self-assembled nanoparticle vaccine with HIV-1 Tat-HPV16 E7 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent anti-tumor immunity in mice. 2012 , 30, 1071-82	36
227	Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer. 2012 , 30, 5417-24	14
226	Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner. 2012 , 30, 5368-72	18
225	Perspectives on Therapeutic HPV Vaccines: Where Are We Now?. 2012 , 341-389	
224	Chemokine binding protein vCCI attenuates vaccinia virus without affecting the cellular response elicited by immunization with a recombinant vaccinia vector carrying the HPV16 E7 gene. 2012 , 25, 411-22	2
223	Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity. 2012 , 114, 51-76	20
222	TLR ligand-peptide conjugate vaccines: toward clinical application. 2012 , 114, 177-201	59
221	Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors. 2012 , 7, e52976	16
220	Quantification of superparamagnetic iron oxide with large dynamic range using TurboSPI. 2012 , 216, 152-60	8
219	Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. 2013 , 132, 335-44	35
218	Histone deacetylase inhibitor AR-42 enhances E7-specific CD8+ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. 2013 , 91, 1221-31	19
217	Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. <i>European Journal of Immunology</i> , 2013 , 43, 2554-65	6.1 118
216	Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. 2013 , 97, 1231-9	39
215	Flagellin enhances tumor-specific CD8+ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. 2013 , 31, 3879-87	54
214	Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors. 2013 , 24, 861-70	23

213	Pore size-optimized periodic mesoporous organosilicas for the enrichment of peptides and polymers. 2013 , 3, 14466	20
212	Immunotherapy in new pre-clinical models of HPV-associated oral cancers. 2013 , 9, 534-43	22
211	A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection. 2013 , 8, e61473	75
210	Cytolytic activity of the human papillomavirus type 16 E711-20 epitope-specific cytotoxic T lymphocyte is enhanced by heat shock protein 110 in HLA-A*0201 transgenic mice. 2013 , 20, 1027-33	9
209	IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. 2013 , 210, 491-502	136
208	Helper cell-independent antitumor activity of potent CD8 T cell epitope peptide vaccines is dependent upon CD40L. 2013 , 2, e27009	3
207	Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adeno-shRNA-SOCS1 virus. 2013 , 43, 1151-9	15
206	Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model. 2013 , 2, 128-34	13
205	HSP70 and modified HPV 16 E7 fusion gene without the addition of a signal peptide gene sequence as a candidate therapeutic tumor vaccine. 2013 , 30, 3020-6	6
204	CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. 2013 , 8, e73145	24
203	In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV-driven tumours. 2014 , 92, 156-63	11
202	Toward multi-analyte bioarray sensors: LAPS-based on-chip determination of a Michaelis-Menten-like kinetics for cell culturing. 2014 , 211, 1410-1415	5
201	Tertiary prevention of cervical cancer. 2014 , 57, 316-24	5
200	SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. 2014 , 74, 6441-51	25
199	Scientific contributions toward successful cancer immunotherapy in The Netherlands. 2014 , 162, 121-6	1
198	Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. 2014 , 3, e953407	29
197	Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. 2014 , 159, 291-305	27
196	Structure-based programming of lymph-node targeting in molecular vaccines. 2014 , 507, 519-22	582

195	Cause and consequence of cancer/testis antigen activation in cancer. 2014 , 54, 251-72	149
194	A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer. 2014 , 58, 132-8	9
193	In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. 2014 , 134, 2742-7	22
192	Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. 2014 , 32, 6956-6962	17
191	Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice. 2014 , 14, 367	27
190	Disintegration and cancer immunotherapy efficacy of a squalane-in-water delivery system emulsified by bioresorbable poly(ethylene glycol)-block-poly lactide. 2014 , 35, 1686-95	25
189	Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. 2014 , 124, 1497-511	51
188	Promises and Challenges with Immunomodulatory Biologics. 2014 , 159-188	
187	Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. 2015 , 2, 15048	6
186	Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. 2015 , 37, 20-38	36
185	Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models. 2015 , 64, 1329-38	22
184	Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication. 2015 , 75, 3279-91	39
183	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. 2015 , 709-738.e8	
182	Bacillus subtilis spores as adjuvants for DNA vaccines. 2015 , 33, 2328-34	12
181	Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression. 2015 , 3, 1042-51	53
180	Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death. 2015 , 21, 781-94	65
179	Anti-tumor effects of genetic vaccines against HPV major oncogenes. 2015 , 11, 45-52	13
178	Targeting tumor vasculature: expanding the potential of DNA cancer vaccines. 2015 , 64, 1339-48	18

177	Moving forward with human papillomavirus immunotherapies. 2016 , 12, 2875-2880	8
176	Combined Cancer Immunotherapy Against Aurora Kinase A. 2016 , 39, 160-70	3
175	Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. 2016 , 8, 367ra166	74
174	Best cooperative partner selection and input resource reallocation using DEA. 2016 , 67, 1221-1237	12
173	Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8+ T-cell Immunity. 2016 , 4, 823-834	16
172	Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells. 2016 , 76, 6017-6029	85
171	Perspectives for therapeutic HPV vaccine development. 2016 , 23, 75	109
170	Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. 2016 , 4, 68	20
169	The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response. 2016 , 2, 44-51	5
168	Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies. 2016 , 21, 769-85	10
167	Sequence-based approach for rapid identification of cross-clade CD8+ T-cell vaccine candidates from all high-risk HPV strains. 2016 , 6, 39	11
166	Current state in the development of candidate therapeutic HPV vaccines. 2016 , 15, 989-1007	66
165	GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth. 2017 , 35, 1509-1516	3
164	Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors. 2017 , 16, 1922-1933	10
163	An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. 2017 , 7, 252	99
162	Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice. 2017 , 66, 451-460	10
161	The current state of therapeutic and T cell-based vaccines against human papillomaviruses. 2017 , 231, 148-165	34
160	HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy. 2017 , 13, 291-297	20

- 159 A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8 T cell responses and antitumor effect. **2017**, 35, 6459-6467 12
- 158 In vivo electroporation enhances vaccine-mediated therapeutic control of human papilloma virus-associated tumors by the activation of multifunctional and effector memory CD8 T cells. **2017**, 35, 7240-7249 10
- 157 Importance of Vaccination in Uterine Cancer Prevention in Adolescence. **2017**, 02,
- 156 Peptide-Based Therapeutic Cancer Vaccines. **2018**, 249-261 2
- 155 Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model. **2018**, 67, 627-638 19
- 154 Designing of Epitope-Focused Vaccine by Targeting E6 and E7 Conserved Protein Sequences: An Immuno-Informatics Approach in Human Papillomavirus 58 Isolates. **2018**, 10, 251-260 10
- 153 Using MRI cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine. **2018**, 80, 304-316 22
- 152 Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8 T Cell Responses. **2018**, 9, 2968 14
- 151 Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication. **2018**, 6, 146 33
- 150 Critical role for the Ly49 family of class I MHC receptors in adaptive natural killer cell responses. **2018**, 115, 11579-11584 12
- 149 A comprehensive in silico analysis for identification of therapeutic epitopes in HPV16, 18, 31 and 45 oncoproteins. **2018**, 13, e0205933 19
- 148 Optimized Gemcitabine Therapy in Combination with E7 Peptide Immunization Elicits Tumor Cure by Preventing Ag-Specific CTL Inhibition in Animals with Large Established Tumors. **2018**, 37, 850-860 5
- 147 Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice. **2018**, 6, 1301-1313 19
- 146 Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses. **2018**, 6, 870-880 13
- 145 Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control. **2018**, 25, 7 14
- 144 Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response. **2018**, 13, e0191311 25
- 143 CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8 T-cell responses by upregulating MHC-I expression. **2019**, 38, 7166-7180 17
- 142 HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. **2019**, 8, e1629259 26

141	Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFN γ receptor signaling. 2019 , 7, 152	44
140	Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease. 2019 , 37, 2915-2924	14
139	Combined Inhibition of TGF- β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. 2019 , 8,	51
138	A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4 T and Natural Killer Cells. 2019 , 79, 783-794	7
137	Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection. 2019 , 7, 25	18
136	Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo. 2019 , 69, 279-288	18
135	A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins. 2019 , 9, 18713	4
134	New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation. 2019 , 70, 409-424	30
133	Ferritin nanoparticle-based SpyTag/SpyCatcher-enabled click vaccine for tumor immunotherapy. 2019 , 16, 69-78	38
132	Cell density quantification with TurboSPL: R* mapping with compensation for off-resonance fat modulation. 2020 , 33, 469-481	1
131	Generation of highly activated, antigen-specific tumor-infiltrating CD8 T cells induced by a novel T cell-targeted immunotherapy. 2020 , 9, 1782574	0
130	Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine. 2020 , 16, e1008827	5
129	In vivo detection of antigen-specific CD8 T cells by immuno-positron emission tomography. 2020 , 17, 1025-1032	22
128	Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations. 2020 , 11, 1750	3
127	Adenoviral vaccines promote protective tissue-resident memory T cell populations against cancer. 2020 , 8,	5
126	Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy. 2020 , 9, 1851539	2
125	Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines. 2020 , 4, 636-648	23
124	Development of multiepitope therapeutic vaccines against the most prevalent high-risk human papillomaviruses. 2020 , 12, 459-479	2

123	Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens. 2020 , 8,	2
122	HPV16-E7 Protein T Cell Epitope Prediction and Global Therapeutic Peptide Vaccine Design Based on Human Leukocyte Antigen Frequency: An In-Silico Study. 2020 , 27, 1-14	5
121	Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors. 2021 , 40, 37	1
120	Therapeutic cancer vaccines. 2021 , 21, 360-378	125
119	Tumor Immunity and Immunotherapy for HPV-Related Cancers. 2021 , 11, 1896-1912	11
118	Tumor targeting nanoparticle E7-HSP110-RGD elicits potent anti-tumor immune response in a CD8-dependent manner in cervical cancer-bearing mouse model. 2021 , 17, 3529-3538	1
117	Potential role of micro ribonucleic acids in screening for anal cancer in human papilloma virus and human immunodeficiency virus related malignancies. 2021 , 12, 59-83	0
116	Development of a Novel Mouse Model of Spontaneous High-Risk HPVE6/E7-Expressing Carcinoma in the Cervicovaginal Tract. 2021 , 81, 4560-4569	3
115	In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses. 2021 , 63, 1192-1222	1
114	Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine. 2021 , 28, 63	3
113	Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model. 2021 , 285, 119945	0
112	Optimal combination treatment regimens of vaccine and radiotherapy augment tumor-bearing host immunity. 2021 , 4, 78	3
111	Peptide Vaccines.	1
110	Virus Infections. 1-81	9
109	Cancer Metastasis: Biological and Clinical Aspects, Gynaecological Cancer. 2000 , 381-420	2
108	Peptide vaccines against cancer. 2005 , 123, 115-36	13
107	Therapeutic Human Papillomavirus Vaccines. 2004 , 345-375	2
106	Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. 1995 , 6, 847-74	17

105	DNA vaccines targeting dendritic cells for the immunotherapy of cancer. 1998 , 451, 295-304	5
104	T-Cell and NK-Mediated Surveillance of Cancer. 1998 , 249-271	1
103	Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. 1994 , 186, 217-53	36
102	The Function. 1997 , 217-369	5
101	Recognition by Immune Cells. 1997 , 371-447	1
100	Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. 1994 , 39, 105	2
99	THERAPEUTIC VACCINES FOR CONTROL OF HUMAN PAPILLOMAVIRUS CHRONIC INFECTIONS. 2000 , 273-293	1
98	Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. 7 , 726-733	5
97	Prospects for human papillomavirus vaccine development: emerging HPV vaccines. 1998 , 10, 15-9	19
96	Human papillomavirus infection and cervical carcinoma. 2000 , 43, 363-80	16
95	Virus-specific CTL responses induced by an H-2K(d)-restricted, motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus. 2002 , 83, 429-438	28
94	Identification of new cytotoxic T-cell epitopes on the 38-kilodalton lipoglycoprotein of Mycobacterium tuberculosis by using lipopeptides. 1998 , 66, 3190-7	24
93	Differential effects of flanking residues on presentation of epitopes from chimeric peptides. 1994 , 68, 5306-10	34
92	A short peptide eluted from the H-2Kb molecule of a polyomavirus-positive tumor corresponds to polyomavirus large T antigen peptide at amino acids 578 to 585 and induces polyomavirus-specific immunity. 1996 , 70, 3093-7	19
91	Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: implications for epitope-based antiviral vaccines. 1997 , 71, 7429-35	30
90	Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. 1997 , 71, 3998-4004	60
89	Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. 1999 , 73, 5981-93	44
88	Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. 1999 , 73, 6166-70	29

87	Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. 1999 , 73, 7877-81	51
86	Human papillomavirus infection. 1996 , 312, 522-3	2
85	Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. 2001 , 54, 669-74	121
84	Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. 2002 , 9, 675-87	8
83	Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. 2002 , 109, 651-659	190
82	Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. 2002 , 109, 651-9	106
81	Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. 2001 , 108, 669-678	210
80	Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. 2000 , 96, 91-99	15
79	Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. 2012 , 7, e48463	17
78	Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects. 2013 , 8, e71216	3
77	An elite controller of picornavirus infection targets an epitope that is resistant to immune escape. 2014 , 9, e94332	5
76	Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling). 2014 , 9, e113461	13
75	Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy. 2015 , 10, e0138458	14
74	Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine. 2015 , 10, e0138686	32
73	Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach. 2015 , 10, e0138722	7
72	C3-Luc Cells Are an Excellent Model for Evaluation of Cellular Immunity following HPV16L1 Vaccination. 2016 , 11, e0149748	4
71	GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression. 2017 , 12, e0174038	6
70	Vaccine Trials for the Clinician: Prospects for Tumor Antigens. 1997 , 2, 284-299	14

69	A novel intracellular antibody against the E6 oncoprotein impairs growth of human papillomavirus 16-positive tumor cells in mouse models. 2016 , 7, 15539-53	20
68	Using lymph node swelling as a potential biomarker for successful vaccination. 2016 , 7, 35655-35669	6
67	GENITAL PAPILLOMAVIRUS INFECTION. 2000 , 259-272	1
66	The role of vaccines in cancer prevention. 2001 , 106, 283-306	2
65	Vaccine Strategies for Colorectal Cancer. 2002 , 795-809	
64	Cancer vaccines. 2003 , 163-182	
63	Biologic Therapy for Gynecologic Malignancies. 2004 , 953-968	
62	Targeting Viral Antigens for the Treatment of Malignancies. 2004 , 49-64	
61	Zervixkarzinom. 2004 , 1113-1151	
60	Mucosal vaccines for HPV. 2005 , 16, 327-332	
59	Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides. 1994 , 187, 97-104; discussion 104-12	5
58	Strategies for studying mouse and human immune responses to human papillomavirus type 16. 1994 , 187, 78-86; discussion 86-96	3
57	Evasion of host immune responses by tumours and viruses. 1994 , 187, 245-56; discussion 256-60	2
56	Cancer-Specific Vaccines. 2008 , 649-669	
55	The Prognostic Significance of Tumor-Infiltrating Lymphocytes. 2010 , 385-407	
54	Antigen-targeted, synthetic vaccines for metastatic cancer. 2011 , 103-125	
53	SA-4-1BBL: A Novel Form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines. 2014 , 347-386	
52	Reflections on Cancer Vaccines. 2014 , 65-68	

- 51 Murine Cytotoxic T Cell Responses to Human Papillomavirus E7 Protein. **1994**, 213-218
- 50 Fine Characterization of the HPV16 E7 49-57 Tumor Protective Cytotoxic T Cell Epitope **1994**, 275-281
- 49 HPV 16-Derived Synthetic Peptides with Ability to Upregulate MHC Class I Expression on RMA-S or T2 Cells, as Detected by Enzyme Immunoassay. **1994**, 201-205
- 48 Vaccines Against HPV of the Uterine Cervix: Problems in Clinical Applicability. **1995**, 117-121
- 47 Vaccines against Human Papillomaviruses and Associated Tumors. **1995**, 157-169 1
- 46 Role of Ligand Density in T Cell Reactions. **1996**, 191-206
- 45 Virale Karzinogenese. **1997**, 22-39
- 44 Immunological Aspects of the E6 and E7 Oncogenes: Tools for Diagnosis and Therapeutic Intervention. **1997**, 137-165
- 43 Vaccination Strategies to Induce T-Cell Immunity Against Tumours. **1997**, 137-149
- 42 Gene Therapy. **1997**, 417-444
- 41 Cancer Immunotherapy. **1999**, 170-204
- 40 Peptide Vaccination. **1999**, 349-355
- 39 Anti-tumour effect of in situ vaccines combined with VEGFR inhibitors in the treatment of metastatic cervical cancer. **2021**, 101, 108302
- 38 Vaccines as Immunotherapy. **2021**, 31-61 0
- 37 Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. **2001**, 108, 669-78 114
- 36 Immunoprevention of Cervical Cancer. **2005**, 449-459
- 35 Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. **1995**, 84, 298-303 26
- 34 Immunization against endogenous retroviral tumor-associated antigens. **2001**, 61, 7920-4 55

33	Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. 2007 , 7, 2	49
32	Active immunization combined with cisplatin confers enhanced therapeutic protection and prevents relapses of HPV-induced tumors at different anatomical sites.. 2022 , 18, 15-29	1
31	Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8 T Cell Responses with Antitumor Activity.. 2022 ,	0
30	Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials.. 2022 , 14,	0
29	Anticancer Vaccination with Immunogenic Micelles That Capture and Release Pristine CD8 T-Cell Epitopes and Adjuvants.. 2022 ,	0
28	H1 ^o histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. 2002 , 72, 285-296	12
27	Peptides for Vaccine Development.. 2022 ,	1
26	Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16 cancer.. 2021 , 1	0
25	TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas.	0
24	Image_1.PDF. 2020 ,	
23	Table_1.DOCX. 2020 ,	
22	Activation of Dendritic Cells and Induction of T Cell Responses by Hpv 16 L1/E7 Chimeric Virus-Like Particles are Enhanced by Cpg ODN or Sorbitol. 2004 , 9, 479-489	13
21	A Virosomal Immunization Strategy against Cervical Cancer and Pre-Malignant Cervical Disease. 2006 , 11, 717-728	14
20	Designing of multi-epitope chimeric vaccine using immunoinformatic platform by targeting oncogenic strain HPV 16 and 18 against cervical cancer. 2022 , 12,	1
19	Eradication of Established Tumors by Vaccination With Recombinant Bordetella pertussis Adenylate Cyclase Carrying the Human Papillomavirus 16 E7 Oncoprotein. 2005 , 65, 641-649	25
18	In silico design of a multi-epitope vaccine against HPV16/18. 2022 , 23,	0
17	Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer. 2022 , 10, e004709	0
16	Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus. 2022 , 14, 4339	0

15	Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice. 13,	0
14	Murine Models of Chronic Viral Infections and Associated Cancers. 2022 , 56, 649-667	0
13	Effects of hypoxia on antigen presentation and T cell-based immune recognition of HPV16-transformed cells. 13,	0
12	Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy. 13,	0
11	Efficacy and synergy with cisplatin of an adenovirus vectored therapeutic E1E2E6E7 vaccine against HPV genome positive C3 cancers in mice.	0
10	Human Melanoma Patients Recognize an HLA-A1-Restricted CTL Epitope from Tyrosinase Containing Two Cysteine Residues: Implications for Tumor Vaccine Development. 1998 , 160, 2099-2106	19
9	Superdominance Among Immunodominant H-2Kb-Restricted Epitopes and Reversal by Dendritic Cell-Mediated Antigen Delivery. 1998 , 160, 3163-3169	18
8	Enhancement of Tumor Outgrowth Through CTL Tolerization After Peptide Vaccination Is Avoided by Peptide Presentation on Dendritic Cells. 1998 , 160, 4449-4456	16
7	Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligopeptide Peptide. 1998 , 161, 3186-3194	24
6	Th2-Type CD4+ Cells Neither Enhance nor Suppress Antitumor CTL Activity in a Mouse Tumor Model. 1998 , 161, 2421-2427	13
5	Cutting Edge: Passive But Not Active CD8+ T Cell-Based Immunotherapy Interferes with Liver Tumor Progression in a Transgenic Mouse Model. 1998 , 161, 5133-5137	9
4	FLT3-Ligand Administration Inhibits Liver Metastases: Role of NK Cells. 1998 , 161, 6164-6170	11
3	Assessment of Immunogenicity of Human Melan-A Peptide Analogues in HLA-A*0201/Kb Transgenic Mice. 1999 , 162, 3566-3573	14
2	CD4+ Tumor-Infiltrating Lymphocytes in Cervical Cancer Recognize HLA-DR-Restricted Peptides Provided by Human Papillomavirus-E7. 1999 , 163, 5715-5722	5
1	Introduction: Immune System & Modulation of Immune System. 2023 , 1-40	0